Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sorafenib
Drug ID BADD_D02058
Description Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
Indications and Usage Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Marketing Status Prescription
ATC Code L01EX02
DrugBank ID DB00398
KEGG ID D08524
MeSH ID D000077157
PubChem ID 216239
TTD Drug ID D0W5HK
NDC Product Code 0378-1201; 68554-0073; 12527-8488; 63850-8051; 47049-848; 50419-488; 43744-545
Synonyms Sorafenib | Nexavar | BAY 43-9006 | BAY 43 9006 | BAY 439006 | Sorafenib N-Oxide | Sorafenib N Oxide | BAY-673472 | BAY 673472 | BAY 545-9085 | BAY 545 9085 | BAY 5459085 | BAY-545-9085 | BAY5459085 | Sorafenib Tosylate | 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
Chemical Information
Molecular Formula C21H16ClF3N4O3
CAS Registry Number 284461-73-0
SMILES CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fluid retention20.01.02.003; 14.05.06.0020.003730%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Folliculitis23.09.04.007; 11.01.12.018--
Formication19.10.02.010; 17.02.06.0180.000533%Not Available
Fracture15.08.02.001; 12.04.02.001--
Frequent bowel movements07.02.04.0020.003730%Not Available
Fungal infection11.03.05.001--Not Available
Furuncle23.09.01.004; 11.02.05.0080.000799%Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.016784%
Gamma-glutamyltransferase increased13.03.01.0110.002931%
Gangrene23.06.06.001; 11.02.01.003; 24.04.05.0030.000533%Not Available
Gastric cancer16.13.03.001; 07.21.02.0010.000278%Not Available
Gastric haemorrhage24.07.02.007; 07.12.01.0010.001865%
Gastric ulcer07.04.03.0020.005062%
Gastric ulcer haemorrhage24.07.02.003; 07.04.03.0050.001332%Not Available
Gastric ulcer perforation07.04.03.0060.000799%Not Available
Gastritis07.08.02.0010.001865%
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.0010.000799%Not Available
Gastroenteritis viral11.05.04.005; 07.19.03.0050.000799%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal necrosis24.04.08.006; 07.15.01.0030.000139%
Gastrointestinal pain07.01.05.0050.001332%
Gastrointestinal perforation07.04.04.0010.000139%Not Available
Generalised oedema14.05.06.007; 08.01.07.004--
Genital rash23.03.13.016; 21.10.01.0090.002131%Not Available
Gingival bleeding24.07.02.010; 07.09.07.0010.004529%Not Available
Gingival pain07.09.04.0010.001865%
Gingival swelling07.05.04.0030.000533%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 33 Pages